No Data
No Data
Guangxi Hechi Chemical (000953.SZ): a total of 0.8781 million shares have been repurchased, and there is a risk that the repurchase plan cannot be successfully implemented.
On August 5th, Gelonhui reported that Guangxi Hechi Chemical (000953.SZ) had repurchased 878,100 shares through a stock repurchase dedicated securities account in the centralized bidding trading method as of July 31, 2024, accounting for 0.24% of the company's total share capital. The highest fill price at which shares were purchased was 2.64 yuan/share, and the lowest fill price was 2.47 yuan/share, with a total transaction value of 2,239,646.00 yuan (excluding transaction fees). The implementation of the company's share repurchase plan complies with relevant laws and regulations and meets the established plan. As of August 5, 2024, the company's stock closing price was 4.
Subdued Growth No Barrier To Guangxi Hechi Chemical Co., Ltd (SZSE:000953) With Shares Advancing 30%
Guangxi Hechi Chemical (000953.SZ): First repurchase of 0.24% of shares.
On July 18th, Gelunhui reported that Guangxi Hechi Chemical (000953.SZ) repurchased company shares for the first time through a share repurchase special securities account in a centralized bidding trading manner. A total of 878,100 shares were repurchased, accounting for 0.24% of the company's total share capital. The highest fill price for the purchase of shares was 2.64 yuan/share, and the lowest fill price was 2.47 yuan/share. The total transaction amount was 2,239,646.00 yuan (excluding transaction fees).
Guangxi Hechi Chemical: 2024 Interim Performance Forecast
Guangxi Hechi Chemical Co., Ltd (SZSE:000953) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely
Hehua Co., Ltd. (000953.SZ): General manager changed to Jiang Luben
On May 22, Ge Longhui Co., Ltd. (000953.SZ) announced that the company held the 16th meeting of the 10th board of directors on May 22, 2024 to review and pass the “Proposal on Changing the Company's General Manager”. The board of directors of the company recently received a written resignation report from Mr. Qin Baoming, a non-independent director and general manager of the company. Mr. Qin Baoming applied to resign as general manager of the company due to job adjustments. After his resignation, Mr. Qin Baoming continued to serve as a non-independent director of the company and a director of Chongqing Nansong Pharmaceutical Technology Co., Ltd., a holding subsidiary. His resignation report became effective when it was delivered to the board of directors. As of the date of disclosure of the announcement,
No Data